SolaranRx Inc.
Theranostic for metastatic melanoma
This article was originally published in Start Up
Executive Summary
SolaranRx Inc. is jumping on the theranostics bandwagon by tackling the deadly skin cancer melanoma, which for advanced cases has a staggering survival rate of only six months and a one-year mortality of 75%. The company’s lead compound, SRX-1177, is a novel peptide linked to a radioisotope that can preferentially attach to melanocortin-1, a unique receptor overexpressed on melanoma cells.